Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 10, 2022 7:51pm
174 Views
Post# 35164235

RE:Anyone here know the strategy of TH1902 going forward?

RE:Anyone here know the strategy of TH1902 going forward?Well it has been some communication with larger shareholders ONLY so the company realizes there were some need for some clarification to keep 
 them  informed but in their communication strategies there is no need to inform the smaller shareholders? I guess they tried to mitigate the negative impact of a sudden event in order to avoid panic well but the looks of the price action it seems that didn't work out. From knowing the halt to announcing a protocol amendment in matter of few hours they came up with their contingency plan which cost resources? I don't think that plan was discussed/analyzed and considered in such short time so although not yet finalized why not come out with the rationale? Again less guesswork and more clarity about an organization can help to understand the situation where they are at/where they plans can potentially take them. I don't know what potion of selling is the larger informed shareholders but if they had a reasonable explanation most of the sellers are the less informed investors. Nobody can predict the outcome of a clinical trial but for god sake if you have a plan share it and what is the responsibility for it to your knowledge! Some investors would take the bite and some wouldn't as it is now the sellers are in wonderland! And the company hasn't done anything but issuing a PR which raises more questions than answers!! Totally bizarre communication strategies, confusion, panic and fear!! No wonder the low demand at multi years lows....
Joemare wrote: Isn't insane that it has not been communicated? What is the protocol amendment? What are the FDA timelines?  Where are they with proof of concept?  How can a CEO not want to communicate this to shareholders ?  

I think they are clueless. I certainly hope I'm wrong as I'm losing big here. 

 


<< Previous
Bullboard Posts
Next >>